Research development

Odyssey Therapeutics Expands Leadership Team with Key Appointments in Research Development and Strategy

Jeff HermesPh.D., Former Head of R&D at Kallyope, Roche and Merck, Joins as Executive Vice President of Enabling Sciences

Natalie DalePh.D., promoted to Head of Research Operations and Portfolio Strategy

BOSTON, November 9, 2022 /PRNewswire/ — Odyssey Therapeutics, Inc., a biotechnology company pioneering precision immunomodulators and next-generation oncology drugs, today announced the appointment of Jeff HermesPh.D., as executive vice president of Enabling Sciences and promotion of Natalie Dale, Ph.D., to the newly created position of Head of Research Operations and Portfolio Strategy. In these roles, Dr. Hermes will oversee the development and implementation of capabilities for Odyssey’s platform approaches and technologies, and Dr. Dales will lead science strategy and facilitate collaboration across the organization. .

“I am delighted to welcome Jeff and Natalie to their new roles as I believe they will be a great contributor to the business during this time of rapid growth,” said Gary D. Glick, Ph.D., Founder and CEO of Odyssey Therapeutics. “Jeff’s leadership in screening, pharmacology and translational sciences, as well as his experience in the drug discovery process, will be invaluable as we continue to create the next generation of transformative medicines for patients with immunological diseases and severe oncology. Additionally, Natalie has played a critical role in helping shape Odyssey’s research programs and strategy during her time here, and she will continue to execute our portfolio strategy and streamline efforts across the company. ‘company. »

Dr. Hermes will be responsible for advancing the company’s proteomics, small molecule detection platforms and transcription factor capabilities to discover next-generation drugs. Dr. Dales will lead scientific strategy and decision-making to advance the pipeline to clinical entry, create connectivity and cohesion across programs and capabilities, and oversee the use of resources to drive efficiency and synergies across the organization.

Jeff HermesPh.D., Executive Vice President of Enabling Sciences

Dr. Hermes is a seasoned professional with over 30 years of experience in biochemistry, pharmacology and in vitro sciences in the biopharmaceutical industry. Most recently, Dr. Hermes served as Vice President of In Vitro Pharmacology at Kallyope, where he led in vitro pharmacology, screening and enzymology efforts to create transformational small molecule therapies that act on the gut-brain axis. Previously, he was Head of Screening and Translational Enzymology at Roche, where he was responsible for guiding early-stage efforts from discovery to nominating development candidates. Prior to Roche, Dr. Hermes spent more than 25 years at Merck and eventually served as Executive Director and Head of Protein Screening and Science, where he oversaw efforts to find results, identify leads and translational science in various therapeutic areas. He got his doctorate. diploma at The University of Wisconsin-Madison and completed postdoctoral training at Harvard University.

Natalie DalePh.D., Head of Research Operations and Portfolio Strategy

Dr. Dales brings over 20 years of experience leading small molecule drug discovery in the pharmaceutical and biotechnology fields. Dr. Dales most recently served as Executive Vice President of Enabling Science for Odyssey. Previously, she spent more than 15 years at Novartis, where she held positions of increasing responsibility, including Executive Director and Head of Portfolio and Strategy for Global Discovery Chemistry. Prior to this role, she led small molecule drug discovery efforts focused on liver, kidney, hematology, oncology and rare diseases. She was also a senior advisor for Novartis Genesis Labs, an in-house innovation incubator that nurtured and funded disruptive concepts to accelerate drug discovery.

About Odyssey Therapeutics

Odyssey Therapeutics is a biotechnology company focused on the discovery, development and commercialization of the next generation of immunomodulators and oncology drugs. Comprised of an expert team of drug hunters, scientists, and industry leaders in fundamental biology, chemistry, and data science, Odyssey transforms drug discovery to accelerate and drive creation and efficient delivery of precision medicines improving the lives of patients. For more information, visit http://www.odysseytx.com/ and follow Odyssey Therapeutics on Twitter (@Odyssey_Tx) and LinkedIn.

SOURCE Odyssey Therapeutics